3 results
Approved WMORecruiting
- To asses the safety and toxicity of peri-ablative sorafenib given in doses of either 200 mg or 400 mg twice daily.- To asses the effect of perioperative sorafenib on the RFA induced mobilization of endothelial progenitor cells and cytokines…
Approved WMOCompleted
To evaluate the efficacy and safety of BIBF 1120 in HCC patients without prior systemic treatment as compared to Sorafenib.
Approved WMORecruiting
The objective of the study is to assess the performance of topical negative pressure therapy application with Prevena* Incision Management System (IMS) versus standard conventional wound therapy (SCWT) on closed median sternal incisions in patients…